EUVIMEDEUVIMED entdecken
Open Access

Radiotherapy in the treatment of primary cutaneous CD4 + small/medium T‐cell lymphoproliferative disorder

Susan Y Wu iD, Ethan P Damron, Jie Xu, Penny Q Fang, Julia Dai, Ranjit Nair, Luis E Malpica Castillo, Luis E Fayad, Carlos A Torres-Cabala iD, L Jeffrey Medeiros, Francisco Vega, Roberto N Miranda und 6 weitere

International Journal of Dermatology · 2025

DOI: 10.1111/ijd.17352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Susan Y Wu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Skin Neoplasms, Lymphoma, T-Cell, Cutaneous, Lymphoproliferative Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder (PCSM‐LPD) is an increasingly recognized entity with heterogeneous management strategies that may include radiotherapy.

Objective

Our aim was to characterize treatment options for PCSM‐LPD, with a focus on the role of radiotherapy.

Methods

This is a retrospective review of 46 patients seen in the Cutaneous Lymphoma Program at the University of Texas MD Anderson Cancer Center, with a clinicopathologic review consistent with PCSM‐LPD. All patients were biopsied and underwent observation, topical/intralesional steroids, and/or radiotherapy. Patients were confirmed to have residual disease prior to radiotherapy.

Results

All patients achieved a complete response (CR). Sixteen patients (35%) received focal radiotherapy, with a CR in 15 (94%). The CR rate following ultra‐low‐dose radiotherapy (4 Gy in 1–2 fractions) was 92%. There was no grade 3 toxicity after radiotherapy. Thirty patients were managed without radiotherapy, with excision and observation or steroids.

Conclusion

Primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder has excellent outcomes, and management strategies may include observation following biopsy, steroids, or radiation. Ultra‐low‐dose radiotherapy results in excellent outcomes with limited toxicity and is effective for persistent lesions after steroidal therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsLymphoma, T-Cell, CutaneousLymphoproliferative DisordersHumansRetrospective StudiesMaleFemaleMiddle AgedAgedAdultAged, 80 and overCD4-Positive T-LymphocytesTreatment OutcomeRemission InductionYoung AdultRadiotherapy Dosage

Stichwörter der Autor:innen

T‐cell lymphoproliferative disordercutaneous lymphomacutaneous neoplasmsimmunoglobulinradiotherapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Susan Y Wu, Carlos A Torres-Cabala

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Wu, S. Y., Damron, E. P., Xu, J., Fang, P. Q., Dai, J., Nair, R., Malpica Castillo, L. E., Fayad, L. E., Torres-Cabala, C. A., Medeiros, L. J., Vega, F., Miranda, R. N., Duvic, M., Pinnix, C. C., Dabaja, B. S., Iyer, S. P., Huen, A. O., & Gunther, J. R. (2025). Radiotherapy in the treatment of primary cutaneous CD4 + small/medium T‐cell lymphoproliferative disorder. International Journal of Dermatology. https://doi.org/10.1111/ijd.17352

Vancouver

Wu SY, Damron EP, Xu J, Fang PQ, Dai J, Nair R, et al. Radiotherapy in the treatment of primary cutaneous CD4 + small/medium T‐cell lymphoproliferative disorder. International Journal of Dermatology. 2025. doi:10.1111/ijd.17352

BibTeX
@article{Wu2025,
  author = {Wu, Susan Y and Damron, Ethan P and Xu, Jie and Fang, Penny Q and Dai, Julia and Nair, Ranjit and Malpica Castillo, Luis E and Fayad, Luis E and Torres-Cabala, Carlos A and Medeiros, L Jeffrey and Vega, Francisco and Miranda, Roberto N and Duvic, Madeleine and Pinnix, Chelsea C and Dabaja, Bouthaina S and Iyer, Swaminathan P and Huen, Auris O and Gunther, Jillian R},
  title = {Radiotherapy in the treatment of primary cutaneous CD4 + small/medium T‐cell lymphoproliferative disorder},
  journal = {International Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ijd.17352}
}
Kostenlos starten →